# Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance

Source: https://onco.cc/trials/nct04285086/  
OnCo record `nct04285086` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Ropeginterferon alfa-2b and Anagrelide in myeloproliferative neoplasms, run by PharmaEssentia, active and no longer recruiting.

## Summary

Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance is a phase 3 interventional study registered as NCT04285086 by PharmaEssentia, with 174 participants enrolled, started 2020-08-25 and due to reach its primary completion in 2024-11-12. Interventions recorded: Ropeginterferon alfa-2b and Anagrelide.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04285086
- Phase: 3
- Setting: A Phase 3, Open-Label, Multicenter, Randomized, Active-controlled Study to Assess PK and Compare the Efficacy, Safety, and Tolerability of P1101 vs Anagrelide as 2nd Line Therapy for Essential Thrombocythemia (SURPASS ET): The Core Study and Its Extension Study.
- Sponsor: PharmaEssentia
- Enrolled: 174

## Sources

- ClinicalTrials.gov NCT04285086: https://clinicaltrials.gov/study/NCT04285086

## Connected records

- cancers: [Myeloproliferative neoplasms (PV, ET, myelofibrosis)](https://onco.cc/cancers/myeloproliferative-neoplasms/)
- drugs: [Anagrelide](https://onco.cc/drugs/anagrelide/), [Ropeginterferon alfa-2b](https://onco.cc/drugs/ropeginterferon-alfa-2b/)
- companies: [PharmaEssentia](https://onco.cc/companies/pharmaessentia/)

---
JSON: https://onco.cc/api/v1/entities/nct04285086.json